BCS1L

Across TCGA pan-cancer cohorts, BCS1L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BCS1L data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BCS1L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCS1L expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

HNSC, GBM, and LSCC are the cancer types where BCS1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.646	0.879	.015	7	view →
GBM	OS	Quartile	All	0.922	0.726	.026	4	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.304	.006	3	view →
PDAC	OS	Quartile	All	0.445	0.692	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BCS1L–HNSC (DFS)

Open the HNSC breakdown →